ARA-290
Research profile · How we handle evidence
ARA-290 is an EPO-derived, non-erythropoietic peptide engineered to interact with repair-related receptor pathways while avoiding the erythropoietic (red blood cell–stimulating) side of erythropoietin. It’s been investigated for tissue protection and modulation of inflammatory and neuropathic processes in animal and clinical contexts.
Evidence Score
Moderate confidence
Category
Therapeutic area
Standard Dose
Daily
Half-life
Plasma elimination
Route
Subcutaneous
Safety Tier
Monitor closely
Overview
ARA-290 is best thought of as an EPO-inspired scaffold designed to steer toward tissue protection rather than hematopoiesis. The most consistent story comes from studies of neuropathic and inflammatory conditions, with human trials shaping what’s actually known.
Mechanism of Action
ARA-290 is best thought of as an EPO-inspired scaffold designed to steer toward tissue protection rather than hematopoiesis. The most consistent story comes from studies of neuropathic and inflammatory conditions, with human trials shaping what’s actually known.
Benefits
- Tissue repair
- Anti-inflammatory
- Neuroprotection
- Does not increase hematocrit
Side Effects
- Generally well-tolerated
- Mild injection site reactions
Contraindications
- Pregnant or breastfeeding women
Structure & Sequence
Verified structure
ARA-290
Sequence illustration backed by PubChem match.
- Amino Acid Sequence
- QEQLERALNSS
- Molecular Weight
- 1,257.3 Da
- Chemical Formula
- C51H84N16O21
- CAS Number
- 1208243-50-8
- InChIKey
- WZTIQQBMSJTRBR-WYKNNRPVSA-N
Stack & Route Context
Stacks with
- BPC-157
- TB-500
Administration
Subcutaneous
Research Status
Research peptide for tissue repair
Approval Status
Phase2
Sports Legal
Permitted
References
- 1View source
ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
2015
- 2View source
Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke
2024
- 3View source
NCT01933529: ARA290 in T2D (clinical trial record)
2013
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.